Testosterone Enanthate for Male Hypogonadism

What Is Male Hypogonadism and How Is It Diagnosed?

Male hypogonadism is a clinical condition in which the testes produce insufficient testosterone, leading to symptoms that affect sexual function, body composition, mood, and energy. Diagnosis requires both biochemical confirmation and symptom assessment. The Endocrine Society's 2018 clinical practice guideline sets the threshold at a total testosterone below 300 ng/dL, measured on two separate morning blood draws [1].

Biochemical Criteria

The Endocrine Society guideline specifies that blood should be drawn between 7:00 and 10:00 AM, when testosterone levels peak. A single low reading is not sufficient. The CDC harmonized cutoff of 264 ng/dL represents the lower bound of the reference range established through mass spectrometry standardization across four population-based cohorts [2]. Free testosterone or bioavailable testosterone measurement becomes necessary when sex hormone-binding globulin (SHBG) levels are abnormal, such as in obesity or liver disease.

Symptom Assessment

Biochemistry alone does not warrant treatment. Clinicians look for a cluster of signs: reduced libido, erectile dysfunction, fatigue, depressed mood, decreased lean mass, or increased body fat. The European Academy of Andrology position statement emphasizes that sexual symptoms, particularly reduced morning erections and low desire, carry the strongest diagnostic predictive value. A 42-year-old man with a total T of 280 ng/dL but no symptoms would typically be monitored rather than treated.

Primary vs. Secondary Hypogonadism

Primary hypogonadism originates in the testes (elevated LH and FSH), while secondary hypogonadism results from hypothalamic or pituitary dysfunction (low or inappropriately normal LH/FSH). This distinction matters because secondary hypogonadism may have reversible causes, including opioid use, hyperprolactinemia, or obesity. The AUA/Endocrine Society joint guideline recommends checking LH, FSH, and prolactin before initiating testosterone replacement therapy (TRT) to rule out pituitary pathology.

How Testosterone Enanthate Works

Testosterone enanthate is a long-acting ester of testosterone dissolved in sesame or cottonseed oil, injected deep into muscle tissue. The ester bond undergoes hydrolysis after injection, releasing free testosterone into the bloodstream over several days. Its half-life of approximately 4.5 days produces a pharmacokinetic profile with a peak at 24 to 48 hours post-injection and a trough by day 7 to 10 [3].

Pharmacokinetic Profile

A pharmacokinetic study published in the Journal of Clinical Endocrinology & Metabolism showed that 200 mg of testosterone enanthate injected intramuscularly produces supraphysiologic peaks (often exceeding 1,000 ng/dL) within the first 48 hours, followed by a decline to near-baseline by day 14. This peak-and-trough pattern is why many clinicians now prefer weekly dosing at lower amounts (75 to 100 mg) rather than biweekly dosing at 200 mg. Splitting the dose reduces the amplitude of hormone fluctuations and may decrease estradiol spikes and mood variability.

Mechanism at the Receptor Level

Free testosterone enters target cells and either binds the androgen receptor directly or is converted to dihydrotestosterone (DHT) by 5-alpha reductase. In muscle and bone, testosterone itself is the primary active androgen. In the prostate and skin, DHT predominates. A portion of circulating testosterone also undergoes aromatization to estradiol via the aromatase enzyme in adipose tissue, which explains why obese men on TRT may need closer monitoring of estradiol levels.

Clinical Evidence: The T-Trials and Beyond

The strongest modern evidence for testosterone therapy in older hypogonadal men comes from the Testosterone Trials (T-Trials), a coordinated set of seven randomized, placebo-controlled trials published in the New England Journal of Medicine in 2016 [4].

T-Trials Design and Results

The T-Trials enrolled 790 men aged 65 and older with total testosterone below 275 ng/dL and symptoms in at least one of three domains: sexual function, physical function, or vitality. Participants received testosterone gel (not enanthate specifically, but results are considered class-applicable by the Endocrine Society). After 12 months, the Sexual Function Trial showed a statistically significant improvement, with testosterone-treated men reporting increased desire and erectile function compared to placebo (P<0.001). The Physical Function Trial demonstrated a modest but significant increase in 6-minute walking distance. The Vitality Trial showed a small improvement in the FACIT-Fatigue score, though the clinical significance of this gain was debatable.

Cardiovascular Safety Data

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, was the first large, randomized cardiovascular outcomes trial of testosterone therapy. Men aged 45 to 80 with hypogonadism and preexisting cardiovascular disease or high cardiovascular risk received transdermal testosterone or placebo for a mean of 33 months. The primary endpoint of major adverse cardiovascular events (MACE) showed no increased risk with testosterone (hazard ratio 0.96, 95% CI 0.78 to 1.17). This trial addressed a long-standing FDA safety concern first raised in 2015.

Bone and Body Composition Evidence

A sub-study of the T-Trials, the Bone Trial, found that one year of testosterone treatment significantly increased volumetric bone mineral density and estimated bone strength at the spine and hip as measured by quantitative CT. Separately, a meta-analysis of 59 RCTs published in the Journal of Clinical Endocrinology & Metabolism found that TRT consistently reduced fat mass by an average of 1.6 kg and increased lean body mass by approximately 1.7 kg.

Standard Dosing Protocols

The FDA-approved prescribing information for testosterone enanthate specifies a dose range of 50 to 400 mg every two to four weeks for male hypogonadism. In clinical practice, most prescribers use a narrower, more frequent regimen to minimize hormonal fluctuations.

Weekly vs. Biweekly Injection

The most commonly prescribed regimen is 100 mg intramuscularly once weekly or 200 mg every two weeks. Weekly dosing at half the biweekly dose produces more stable serum levels. A study in Clinical Endocrinology compared weekly vs. Biweekly protocols and found that weekly injections kept trough testosterone above 400 ng/dL more consistently, whereas biweekly dosing frequently dropped troughs below the therapeutic range.

Dose Titration

Starting dose depends on the patient's baseline testosterone, body weight, and clinical presentation. A typical initiation protocol:

• Starting dose: 75 to 100 mg IM weekly
• First lab check: 6 weeks after initiation, drawn at trough (morning before next injection)
• Target trough: 400 to 700 ng/dL (mid-normal range)
• Dose adjustment: increase or decrease by 25 mg increments based on trough levels and symptom response

Men with higher body mass index may require slightly higher doses due to increased aromatase activity and SHBG suppression. Dose escalation beyond 200 mg weekly is rarely needed and increases the risk of polycythemia and estradiol elevation.

Injection Technique

Testosterone enanthate is administered as a deep intramuscular injection. The ventrogluteal site is preferred over the dorsogluteal due to lower risk of sciatic nerve injury and more consistent absorption. A 22- to 25-gauge needle, 1 to 1.5 inches in length, is standard. Some clinicians now teach subcutaneous injection with a 27-gauge needle for patient convenience, though this is technically off-label. A 2017 study in the Journal of Clinical Endocrinology & Metabolism found that subcutaneous testosterone enanthate achieved comparable steady-state levels to intramuscular injection.

Monitoring and Lab Schedule

Proper monitoring separates responsible TRT from unsupervised hormone use. The Endocrine Society guideline recommends a structured monitoring protocol that extends through the first year and continues annually [1].

Baseline Labs Before Starting

Before the first injection, clinicians should obtain: total testosterone (two morning draws), free testosterone or SHBG, LH, FSH, complete blood count (CBC) with hematocrit, comprehensive metabolic panel, lipid panel, PSA (for men over 40), and estradiol. A baseline DEXA scan is reasonable if osteoporosis risk factors are present.

Follow-Up Timeline

| Timepoint | Labs to Check | Key Targets | |-----------|--------------|-------------| | 6 weeks | Total T at trough, hematocrit | T 400-700 ng/dL, HCT <54% | | 3 months | Total T, hematocrit, PSA, estradiol | Stable T, no PSA spike >1.4 ng/mL | | 6 months | CBC, lipid panel, hepatic function | HCT <54%, LDL not worsening | | 12 months | Full panel (T, CBC, PSA, lipids, E2) | Annual comprehensive review | | Annually | Same as 12-month panel | Ongoing safety surveillance |

Red Flags That Require Dose Reduction or Discontinuation

Hematocrit above 54% is the most common reason for dose adjustment. This threshold comes from the Endocrine Society 2018 guideline, which notes that polycythemia raises the risk of thromboembolic events. If hematocrit exceeds 54%, the clinician should reduce the dose, increase injection frequency (to lower peaks), or temporarily hold therapy. Therapeutic phlebotomy is a bridge measure, not a long-term solution to dose-dependent polycythemia.

Side Effects and Risk Management

Every man considering TRT should understand the common side effects and the difference between expected physiological effects and warning signs that need clinical attention.

Common Side Effects

Acne and oily skin affect roughly 15 to 25% of men starting TRT, driven by increased DHT activity in sebaceous glands. This typically peaks in the first 3 months and often self-resolves. Injection-site pain occurs in about 10% of patients, particularly with thicker-gauge needles or cold oil. Warming the vial to body temperature before injection and using a 25-gauge needle reduces discomfort.

Estradiol-Related Effects

Gynecomastia (breast tissue enlargement) occurs when aromatization converts excess testosterone to estradiol. A review in the Journal of Clinical Endocrinology & Metabolism reported gynecomastia in roughly 10 to 25% of men on TRT, with higher rates in overweight individuals. Estradiol levels above 40 to 50 pg/mL correlate with nipple tenderness and tissue growth. Dose reduction is the first-line intervention. Aromatase inhibitors like anastrozole are sometimes used off-label, but the Endocrine Society guideline does not recommend routine AI use with TRT due to concerns about bone density reduction.

Fertility Suppression

Exogenous testosterone suppresses gonadotropin (LH and FSH) secretion, which reduces or eliminates spermatogenesis. This effect is typically reversible after discontinuation, but recovery may take 6 to 18 months. The American Urological Association guideline on testosterone deficiency explicitly warns against prescribing testosterone to men actively trying to conceive. Alternatives like clomiphene citrate or human chorionic gonadotropin (hCG) preserve fertility while raising endogenous testosterone production.

Polycythemia

Testosterone stimulates erythropoietin and directly activates bone marrow erythroid progenitors. The TRAVERSE trial reported that polycythemia (hematocrit >54%) occurred in 3.5% of testosterone-treated men vs. 0.5% in the placebo group. This is the most clinically significant hematologic side effect and requires structured monitoring as described above.

Who Should Not Use Testosterone Enanthate

Absolute contraindications are narrow but firm. The FDA label and Endocrine Society guidelines agree on the following:

• Breast or prostate cancer: active, known malignancy is a contraindication. Testosterone does not cause prostate cancer, but it may accelerate growth of existing hormonally sensitive tumors.
• Hematocrit above 54% at baseline: treatment should not begin until the underlying cause is addressed.
• Untreated severe obstructive sleep apnea: testosterone may worsen apnea severity, though the TRAVERSE trial did not show a statistically significant increase in sleep apnea events.
• Uncontrolled heart failure: the FDA added a class-wide warning in 2015, though TRAVERSE subsequently showed no excess MACE risk.
• Desire for near-term fertility: as noted, exogenous testosterone suppresses spermatogenesis.

Men with treated, stable prostate cancer represent a gray zone. A growing body of evidence, including a 2023 systematic review in European Urology Focus, suggests that TRT after radical prostatectomy for low-risk prostate cancer does not increase biochemical recurrence, but this remains an individualized decision requiring urologic consultation.

Testosterone Enanthate vs. Other TRT Formulations

Testosterone enanthate is one of several delivery systems. Each carries trade-offs in convenience, cost, and pharmacokinetics.

Enanthate vs. Cypionate

These two esters are nearly interchangeable. Testosterone cypionate has a slightly longer half-life (approximately 5 days vs. 4.5 days) due to one additional carbon in its ester chain, but the clinical difference is negligible. Cypionate is more commonly prescribed in the United States, while enanthate is more prevalent in Europe. Both cost between $30 and $80 per month for generic formulations without insurance.

Enanthate vs. Topical Gels

Gels (AndroGel, Testim) provide daily application and avoid injections. They produce steadier serum levels but carry transfer risk to partners and children through skin contact. The T-Trials used 1% testosterone gel, dosed to achieve a target of 400 to 500 ng/dL. Gels cost significantly more ($200 to $500/month branded) and have lower adherence rates due to daily application requirements.

Enanthate vs. Undecanoate (Aveed)

Testosterone undecanoate is a long-acting injection given every 10 weeks after loading doses. It eliminates the need for weekly injections but requires in-office administration due to a post-injection observation period for pulmonary oil microembolism (POME) reactions. The FDA label for Aveed mandates a 30-minute observation period after each injection. Cost is substantially higher ($1,000 to $1,500 per injection without insurance).

What to Expect: Timeline of Response

Different symptoms respond on different timescales. A comprehensive review in the European Journal of Endocrinology mapped the expected timeline:

• Libido improvement: 3 to 6 weeks, plateau at 6 to 12 months
• Erectile function: 3 to 6 months (may take longer if vascular disease coexists)
• Energy and mood: 3 to 6 weeks for initial improvement, maximal effect by 3 to 6 months
• Body composition changes: fat loss and lean mass gain detectable by 12 to 16 weeks, plateau at 6 to 12 months
• Bone density improvement: 6 to 12 months measurable, continues through 36 months

Men who do not notice any symptomatic improvement by 3 months despite verified trough testosterone levels in the 400 to 700 ng/dL range should undergo reassessment. "Low testosterone" may not have been the primary driver of their symptoms.